Page 14 of 25

PH6.4 | PH6.4 | Constipation Pharmacotherapy — SDL Guide — SDL Guide (Part 2)

Bulk-Forming and Osmotic Laxatives

Bulk-forming and osmotic laxatives are the preferred agents for long-term management of chronic constipation because they are mechanistically aligned with the normal physiology of colonic water handling — they change the physical or osmotic characteristics of stool without directly stimulating the enteric nervous system. They do not cause dependence, do not damage the enteric neurones, and are safe for chronic use in most patients.

Bulk-forming agents (ispaghula/psyllium, methylcellulose, bran): These agents are hydrophilic polysaccharides or cellulose derivatives that absorb water in the gut lumen and swell to form a gel, increasing stool bulk. The physical distension of the colon wall stimulates peristalsis via stretch receptors — a physiological stimulus, not a pharmacological one. They must always be taken with a large glass of water (at least 200–300 mL); taken dry, they can cause oesophageal or intestinal obstruction. Onset is slow (12–72 hours) — these are maintenance agents, not rescue agents. In addition to laxative effect, psyllium (ispaghula husk) has demonstrated lipid-lowering effects (binds bile acids in the gut lumen, increasing hepatic LDL-receptor upregulation) and improves post-prandial glycaemia (slows glucose absorption). Well tolerated; the main adverse effects are initial bloating and flatulence (from fermentation of soluble fibre components) which settle with continued use.

Osmotic laxatives: The defining mechanism is creating an osmotic gradient that draws water into the colon lumen. The two sub-groups differ in their composition, fermentability, and systemic safety profile:

Poorly absorbed salts (Mg(OH)₂, MgSO₄): Act rapidly (within 2–6 hours) via osmotic water draw. Magnesium ions themselves also stimulate cholecystokinin release from the duodenum, which increases intestinal motility. Effective for acute constipation and bowel prep, but not for chronic use — systemic absorption of Mg²⁺ causes hypermagnesaemia in patients with renal failure (neuromuscular depression, respiratory paralysis). Avoid in renal insufficiency.

Lactulose: A synthetic non-absorbable disaccharide (galactose + fructose). Colonic bacteria ferment it to short-chain fatty acids (SCFA), lactic acid, CO₂, and hydrogen — acidifying the colon (pH <6). The acidic environment: (a) acts as an osmotic agent (organic acids draw water); (b) traps ammonium (NH₄⁺) by converting NH₃ to the impermeant NH₄⁺ form — the basis of its use in hepatic encephalopathy (15–45 mL three times daily, titrated to 2–3 soft stools/day). ADRs: bloating, flatulence, and abdominal cramping from gas production — dose-limiting in many patients.

Polyethylene glycol (PEG/macrogol): A high-molecular-weight inert polymer that is not absorbed or fermented by colonic bacteria. It holds water through hydrogen bonding, drawing fluid into the colon without gas production. PEG is the preferred osmotic laxative for long-term use and is also used for bowel preparation (high-dose) before colonoscopy. It is safe in renal failure (unlike Mg salts), does not cause electrolyte imbalance in standard doses, and produces predictable, dose-dependent results without bloating.

Stimulant Laxatives and Stool Softeners

Stimulant laxatives directly activate the enteric nervous system to increase colonic propulsive contractions — a more aggressive approach than bulk-forming or osmotic agents, appropriate for acute episodes of constipation and as rescue therapy but generally unsuitable for indefinite daily use. Understanding the distinction between the anthraquinone and diphenylmethane sub-classes, and recognising the limitations of stool softeners, allows precise and safe prescribing within this group.

Anthraquinone glycosides (senna, cascara): Senna contains sennoside A and B (anthraquinone glycosides). These are inactive pro-drugs that pass through the small intestine unabsorbed and reach the colon, where colonic bacteria hydrolyse them to active anthranols (rhein anthrone, etc.). The active anthranols: (a) stimulate the submucosal (Meissner's) and myenteric (Auerbach's) plexuses, increasing propulsive contractions; (b) inhibit colonic water absorption (anti-absorptive effect). Onset: 6–12 hours after oral dosing. Senna is widely used and generally well tolerated at standard doses. Chronic overuse can cause melanosis coli (benign brown discolouration of the colonic mucosa from lipofuscin-laden macrophages — harmless, but an endoscopic marker of long-term anthraquinone use) and theoretically cathartic colon (enteric neuropathy with prolonged high-dose use — clinical significance debated). Senna is used in pregnancy (particularly second/third trimester) as the sennoside molecule is large and poorly absorbed, with low fetal risk — though high doses are avoided.

Diphenylmethane derivatives (bisacodyl, sodium picosulfate): Bisacodyl is a prodrug — deacetylated by intestinal esterases and colonic bacteria to its active form, which stimulates the myenteric plexus and inhibits water/electrolyte absorption from the colon. Available as oral tablets (onset 6–12 hours) and rectal suppositories (onset 30–60 minutes — useful for acute evacuation). Critical drug interaction: bisacodyl tablets are enteric-coated to protect the active drug from premature hydrolysis in the stomach. Taking bisacodyl within 1 hour of milk or antacids dissolves the enteric coating prematurely (alkali environment dissolves the acid-stable coating) → gastric irritation, cramps, vomiting. This is a commonly tested and commonly committed error. ADRs: abdominal cramping (dose-related), hyponatraemia with overuse (stimulant-induced fluid loss). Sodium picosulfate has a similar mechanism, is used primarily in bowel-prep combinations (e.g. Picolax).

Stool softeners (docusate sodium): Docusate is an anionic surfactant that reduces the surface tension of stool, allowing water and fat to penetrate the stool mass — softening it without stimulating contractions. Its laxative effect is modest and often insufficient as monotherapy in significant constipation; it is most useful as an adjunct to stimulant laxatives in opioid-induced constipation. Minimal ADRs; generally safe for chronic use.

Liquid paraffin (mineral oil): A lubricant laxative that coats the stool surface and colonic mucosa, preventing water reabsorption and easing stool passage. Despite historical use, it is no longer recommended for routine use because: (a) it can be aspirated, especially in elderly and dysphagic patients → lipoid pneumonia (granulomatous inflammation from oil droplets in the lungs — can be fatal); (b) it impairs absorption of fat-soluble vitamins (A, D, E, K) from the gut with prolonged use; (c) it causes perianal soiling and anal leakage. Safer alternatives (PEG, docusate) have replaced it in most clinical settings.

Newer Secretagogues and Prokinetics

The newer secretagogue laxatives — lubiprostone and linaclotide — represent mechanistically distinct additions to the constipation pharmacological armamentarium that address a limitation of older agents: they not only promote laxation but also, in the case of linaclotide, reduce visceral pain in IBS-C. Their mechanisms act on apical epithelial ion channels rather than on the enteric nervous system or stool osmolality, which is why they retain efficacy in patients who have failed conventional laxatives and why they are particularly relevant to IBS-C (where the abdominal pain component is a primary symptom alongside constipation).

Lubiprostone activates ClC-2 (chloride channel type 2) on the apical membrane of intestinal epithelial cells. ClC-2 opening allows Cl⁻ to flow from the cell into the gut lumen; this negative charge draws Na⁺ and water into the lumen osmotically, softening the stool and promoting bowel movements. Unlike CFTR (which is activated by cAMP-dependent phosphorylation in secretory diarrhoea), ClC-2 is constitutively expressed and its activation by lubiprostone is independent of cAMP. Clinical uses: approved for chronic idiopathic constipation (adults), IBS-C (women ≥18 years), and opioid-induced constipation (when PAMORAs are not available). ADRs: nausea (most common, dose-dependent, reduced by taking with food), diarrhoea (if dose is too high). Contraindicated in patients with mechanical bowel obstruction.

Linaclotide is a 14-amino-acid peptide agonist of guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. GC-C activation generates cyclic GMP (cGMP) intracellularly, which: (a) activates CFTR (the chloride channel also targeted by cholera toxin's cAMP pathway, but via cGMP here) → Cl⁻ secretion into the lumen → water follows → softer stool; (b) activates cGMP-dependent protein kinase, which reduces the activity of pain-sensing submucosal sensory afferents (specifically, cGMP crosses into subepithelial sensory neurones to reduce sodium channel-mediated visceral pain signalling). This dual action — pro-secretory + analgesic — makes linaclotide particularly effective for IBS-C, where both constipation and abdominal pain must be addressed. Clinical uses: IBS-C and chronic idiopathic constipation. ADRs: diarrhoea (most common, dose-limiting). Contraindicated in patients under 6 years (risk of dehydration from diarrhoea) and in bowel obstruction.

Prucalopride (5-HT₄ agonist, colonic-selective) is covered in the prokinetics module (gi1-prokinetic-antiemetic) but is mentioned here as a laxative option: it enhances high-amplitude propagated contractions in the colon and is approved for adults with chronic constipation who have not responded adequately to other laxatives.